Morgan Stanley analyst Terence Flynn upgraded C4 Therapeutics to Equal Weight from Underweight with a price target of $1, down from $3. The analyst cites valuation for the upgrade with the shares down 74% year-to-date. The firm says C4 made the decision to discontinue development due to insufficient single agent efficacy and will instead prioritize the development of CFT7455 and CFT1946.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CCCC:
- C4 Therapeutics price target lowered to $7 from $17 at H.C. Wainwright
- C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics reports Q3 EPS (55c), consensus (66c)
- C4 Therapeutics announces upcoming data on Phase 1/2 trial of CFT7455, CFT8634
- C4 Therapeutics price target lowered to $2 from $5 at BofA